Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Miko Yamada is active.

Publication


Featured researches published by Miko Yamada.


Wiley Interdisciplinary Reviews-nanomedicine and Nanobiotechnology | 2015

Therapeutic gold, silver, and platinum nanoparticles

Miko Yamada; Matthew Foote; Tarl W. Prow

There are an abundance of nanoparticle technologies being developed for use as part of therapeutic strategies. This review focuses on a narrow class of metal nanoparticles that have therapeutic potential that is a consequence of elemental composition and size. The most widely known of these are gold nanoshells that have been developed over the last two decades for photothermal ablation in superficial cancers. The therapeutic effect is the outcome of the thickness and diameter of the gold shell that enables fine tuning of the plasmon resonance. When these metal nanoparticles are exposed to the relevant wavelength of light, their temperature rapidly increases. This in turn induces a localized photothermal ablation that kills the surrounding tumor tissue. Similarly, gold nanoparticles have been developed to enhance radiotherapy. The high-Z nature of gold dramatically increases the photoelectric cross-section. Thus, the photoelectric effects are significantly increased. The outcome of these interactions is enhanced tumor killing with lower doses of radiation, all while sparing tissue without gold nanoparticles. Silver nanoparticles have been used for their wound healing properties in addition to enhancing the tumor-killing effects of anticancer drugs. Finally, platinum nanoparticles are thought to serve as a reservoir for platinum ions that can induce DNA damage in cancer cells. The future is bright with the path to clinical trials is largely cleared for some of the less complex therapeutic metal nanoparticle systems.


The Journal of Pathology | 2011

Erythropoietin protects against apoptosis and increases expression of non-neuronal cell markers in the hypoxia-injured developing brain†

Miko Yamada; Christopher J. Burke; Paul B. Colditz; David W. Johnson; Glenda C. Gobe

Erythropoietin (EPO) is a cytokine hormone with cytoprotective effects in many tissues including the brain. Although the benefits of administration of recombinant human EPO (rhEPO) for neonatal hypoxic brain injury have been demonstrated in neuronal tissue, the effect on non‐neuronal cell populations is unclear. We tested the hypothesis that rhEPO would not only protect neuronal cells but also glial cells at a stage of brain development where their maturation was particularly sensitive, and also protect the vasculature. This was evaluated in a rat model of hypoxic injury. 1000 IU/kg rhEPO was delivered intraperitoneally at the start of 4 h hypoxia or normoxia. Treatment groups of neonatal rats (day of birth, at least N = 10 per group) were as follows: normoxia; normoxia plus rhEPO; hypoxia (8% FiO2 delivered in temperature‐controlled chambers); and hypoxia plus rhEPO. Day of birth in rats is equivalent to human gestation of 28–32 weeks. The effects of rhEPO administration, especially to non‐neuronal cell populations, and the associated molecular pathways, were investigated. Apoptosis was increased with hypoxia and this was significantly reduced with rhEPO (p < 0.05). The neuronal marker, microtubule‐associated protein‐2, increased in expression (p < 0.05) when apoptosis was significantly reduced by rhEPO. In addition, compared with hypoxia alone, rhEPO‐treated hypoxia had the following significant protein expression increases (p < 0.05): the intermediate filament structural protein nestin; myelin basic protein (oligodendrocytes); and glial fibrillary acidic protein (astrocytes). In conclusion, rhEPO protects the developing brain via anti‐apoptotic mechanisms and promotes the health of non‐neuronal as well as neuronal cell populations at a time when loss of these cells would have long‐lasting effects on brain function. Copyright


PLOS ONE | 2014

Microneedle Enhanced Delivery of Cosmeceutically Relevant Peptides in Human Skin

Yousuf H. Mohammed; Miko Yamada; Lynlee L. Lin; Jeffrey E. Grice; Michael S. Roberts; Anthony P. Raphael; Heather A. E. Benson; Tarl W. Prow

Peptides and proteins play an important role in skin health and well-being. They are also found to contribute to skin aging and melanogenesis. Microneedles have been shown to substantially enhance skin penetration and may offer an effective means of peptide delivery enhancement. The aim of this investigation was to assess the influence of microneedles on the skin penetration of peptides using fluorescence imaging to determine skin distribution. In particular the effect of peptide chain length (3, 4, 5 amino acid chain length) on passive and MN facilitated skin penetration was investigated. Confocal laser scanning microscopy was used to image fluorescence intensity and the area of penetration of fluorescently tagged peptides. Penetration studies were conducted on excised full thickness human skin in Franz type diffusion cells for 1 and 24 hours. A 2 to 22 fold signal improvement in microneedle enhanced delivery of melanostatin, rigin and pal-KTTKS was observed. To our knowledge this is the first description of microneedle enhanced skin permeation studies on these peptides.


Vaccine | 2015

Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm.

Penny A. Rudd; Anthony P. Raphael; Miko Yamada; Kaitlin L. Nufer; Joy Gardner; Thuy Le; Natalie A. Prow; Nhung Dang; Wayne A. Schroder; Tarl W. Prow; Andreas Suhrbier

Foroderm is a new cutaneous delivery technology that uses high-aspect ratio, cylindrical silica microparticles, that are massaged into the skin using a 3D-printed microtextured applicator, in order to deliver payloads across the epidermis. Herein we show that this technology is effective for delivery of a non-adjuvanted, inactivated, whole-virus chikungunya virus vaccine in mice, with minimal post-vaccination skin reactions. A single topical Foroderm-based vaccination induced T cell, Th1 cytokine and antibody responses, which provided complete protection against viraemia and disease after challenge with chikungunya virus. Foroderm vaccination was shown to deliver fluorescent, virus-sized beads across the epidermis, with beads subsequently detected in draining lymph nodes. Foroderm vaccination also stimulated the egress of MHC II(+) antigen presenting cells from the skin. Foroderm thus has potential as a simple, cheap, effective, generic, needle-free technology for topical delivery of vaccines.


Pigment Cell & Melanoma Research | 2016

Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation.

Carly Fox; Duncan Lambie; James S. Wilmott; Alex Pinder; Sandra Pavey; Kim-Anh Lê Cao; Taner Akalin; Isil Kilinc Karaarslan; Fezal Ozdemir; Richard A. Scolyer; Miko Yamada; H. Peter Soyer; Helmut Schaider; Brian Gabrielli

Here we have carried out a multiparameter analysis using a panel of 28 immunohistochemical markers to identify markers of transformation from benign and dysplastic naevus to primary melanoma in three separate cohorts totalling 279 lesions. We have identified a set of eight markers that distinguish naevi from melanoma. None of markers or parameters assessed differentiated benign from dysplastic naevi. Indeed, the naevi clustered tightly in terms of their immunostaining patterns whereas primary melanomas showed more diverse staining patterns. A small subset of histopathologically benign lesions had elevated levels of multiple markers associated with melanoma, suggesting that these represent naevi with an increased potential for transformation to melanoma.


Journal of Controlled Release | 2018

Using elongated microparticles to enhance tailorable nanoemulsion delivery in excised human skin and volunteers

Miko Yamada; Hossam Tayeb; Hequn Wang; Nhung Dang; Yousuf H. Mohammed; Sam Osseiran; Paul J. Belt; Michael S. Roberts; Conor L. Evans; Frank Sainsbury; Tarl W. Prow

ABSTRACT This study demonstrates, for the first time, clinical testing of elongated silica microparticles (EMP) combined with tailorable nanoemulsions (TNE) to enhance topical delivery of hydrophobic drug surrogates. Likewise, this is the first report of 6‐carboxyfluorescein (a model molecule for topically delivered hydrophobic drugs) AM1 & DAMP4 (novel short peptide surfactants) used in volunteers. The EMP penetrates through the epidermis and stop at the dermal‐epidermal junction (DEJ). TNE are unusually stable and useful because the oil core allows high drug loading levels and the surface properties can be easily controlled. At first, we chose alginate as a crosslinking agent between EMP and TNE. We initially incorporated a fluorescent lipophilic dye, DiI, as a hydrophobic drug surrogate into TNE for visualization with microscopy. We compared four different coating approaches to combine EMP and TNE and tested these formulations in freshly excised human skin. The delivery profile characterisation was imaged by dye‐ free coherent anti‐Stoke Raman scattering (CARS) microscopy to detect the core droplet of TNE that was packed with pharmaceutical grade lipid (glycerol) instead of DiI. These data show the EMP penetrating to the DEJ followed by controlled release of the TNE. Freeze‐dried formulations with crosslinking resulted in a sustained release profile, whereas a freeze‐dried formulation without crosslinking showed an immediate burst‐type release profile. Finally, we tested the crosslinked TNE coated EMP formulation in volunteers using multiphoton microscopy (MPM) and fluorescence‐lifetime imaging microscopy (FLIM) to document the penetration depth characteristics. These forms of microscopy have limitations in terms of image acquisition speed and imaging area coverage but can detect fluorescent drug delivery through the superficial skin in volunteers. 6‐Carboxyfluorescein was selected as the fluorescent drug surrogate for the volunteer study based on the similarity of size, charge and hydrophobicity characteristics to small therapeutic drugs that are difficult to deliver through skin. The imaging data showed a 6‐carboxyfluorescein signal deep in volunteer skin supporting the hypothesis that EMP can indeed enhance the delivery of TNE in human skin. There were no adverse events recorded at the time of the study or after the study, supporting the use of 6‐carboxyfluorescein as a safe and detectable drug surrogate for topical drug research. In conclusion, dry formulations, with controllable release profiles can be obtained with TNE coated EMP that can effectively enhance hydrophobic payload delivery deep into the human epidermis. Graphical abstsract: Figure. No Caption available.


Proceedings of SPIE | 2017

Advanced imaging approaches for characterizing nanoparticle delivery and dispersion in skin (Conference Presentation)

Tarl W. Prow; Miko Yamada; Nhung Dang; Conor L. Evans

The purpose of this research was to develop advanced imaging approaches to characterise the combination of elongated silica microparticles (EMP) and nanoparticles to control topical delivery of drugs and peptides. The microparticles penetrate through the epidermis and stop at the dermal-epidermal junction (DEJ). In this study we incorporated a fluorescent lipophilic dye, DiI, as a hydrophobic drug surrogate into the nanoparticle for visualization with microscopy. In another nanoparticle-based approach we utilized a chemically functionalized melanin nanoparticle for peptide delivery. These nanoparticles were imaged by coherent anti-Stoke Raman scattering (CARS) microscopy to characterize the delivery of these nanoparticles into freshly excised human skin. We compared four different coating approaches to combine EMP and nanoparticles. These data showed that a freeze-dried formulation with cross-linked alginate resulted in 100% of the detectable nanoparticle retained on the EMP. When this dry form of EMP-nanoparticle was applied to excised, living human abdominal skin, the EMP penetrated to the DEJ followed by controlled release of the nanoparticles. This formulation resulted in a sustained release profile, whereas a freeze-dried formulation without crosslinking showed an immediate burst-type release profile. These data show that advanced imaging techniques can give unique, label free data that shows promise for clinical investigations.


JAMA Dermatology | 2017

Microbiopsy Biomarker Profiling in a Superficial Melanoma Resembling a Pigmented Basal Cell Carcinoma

Priyamvada Sobarun; Van L. T. Hoang; Miko Yamada; Duncan Lambie; H. Peter Soyer; Tarl W. Prow

Microbiopsy Biomarker Profiling in a Superficial Melanoma Resembling a Pigmented Basal Cell Carcinoma The skin microbiopsy device is a minimally invasive and painless technique used as an alternative to conventional biopsy techniques for collecting cells from the epidermis to the papillary dermis for molecular diagnosis and research.1 We used microbiopsy samples and quantitative polymerase chain reaction (qPCR) analysis to differentiate between a histopathologically proven superficial pigmented basal cell carcinoma (BCC) (Figure 1A and B) and a superficial melanoma resembling a pigmented BCC (index lesion from the case patient) (Figure 1C and D).


Nanoscience in Dermatology | 2016

Imaging Nanoparticle Skin Penetration in Humans

Lynlee L. Lin; Miko Yamada; Tarl W. Prow

Our skin, being the primary barrier to foreign materials, is being increasingly exposed to nanoparticles. Nanoparticles contained within personal care products are considered to be relatively safe, but little is known about how these nanoparticles change or interact with the skin. One of the relevant questions that drive the nanotoxicology field is that of nanoparticle penetration into the viable skin. Imaging is particularly suited to studying some nanoparticles but is also limited by several factors, including resolution and specificity. Conventional approaches like electron microscopy and elemental analysis are limited due to the invasive nature of the process. The study of nanoparticle penetration in humans using imaging modalities is now possible given the advancement of clinical skin-imaging technology. In this chapter, we discuss imaging as an approach for investigating nanoparticle penetration and several clinical imaging technologies that have been used for in vivo localization of nanoparticles within the human skin.


Drug Delivery Letters | 2016

Current and Next Generation Topical Anti-Skin Cancer Therapeutics

Kaitlin L. Nufer; Miko Yamada; Tarl W. Prow

Non-melanoma skin cancers are among the most commonly diagnosed skin cancers in the world. Ultraviolet radiation is a primary carcinogen resulting in UV induced mutations, loss of activity in tumour suppressor genes and the over expression of oncogenes in keratinocytes resulting in the development of skin malignancies. With the continued rising rate of non-melanoma skin cancer, topical therapies have become an established treatment method for effective lesion clearance. Current topical therapies include 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate and photodynamic therapy. With high lesion recurrence rates still presenting as an issue following topical treatment, lack of drug selectivity for cancer cells, severe side effects from topical agent use and patient non-compliance due to prolonged treatment periods, new novel topical therapies need to be explored and developed. New therapies must target and clear both subclinical and clinically presenting skin cancers by interrupting the molecular mechanisms that induce and sustain the proliferation of neoplastic cells. Piperlongumine and EBC-46 are two naturally occurring small molecules which have demonstrated effective induction of cancer cell death. Piperlongumine, an amide isolated from the pepper, Piper longum, has demonstrated cancer cell death selectivity yet has no impact on healthy rapidly dividing primary cells. EBC-46 is a diterpene ester isolated from the seed of the fruit, Fontainea picrosperma. EBC-46 induces rapid inflammation and necrosis resulting in tumour ablation following intra-lesional injection. The development of Piperlongumine and EBC-46, as new topical agents offers a unique opportunity to further explore and exploit these selective properties for a more efficient and targeted approach to topical non -melanoma skin cancer treatment.

Collaboration


Dive into the Miko Yamada's collaboration.

Top Co-Authors

Avatar

Tarl W. Prow

University of Queensland

View shared research outputs
Top Co-Authors

Avatar

Glenda C. Gobe

University of Queensland

View shared research outputs
Top Co-Authors

Avatar

David W. Johnson

Princess Alexandra Hospital

View shared research outputs
Top Co-Authors

Avatar

Lynlee L. Lin

University of Queensland

View shared research outputs
Top Co-Authors

Avatar

Nhung Dang

University of Queensland

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David A. Vesey

University of Queensland

View shared research outputs
Top Co-Authors

Avatar

H. Peter Soyer

University of Queensland

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge